Impact of A Cargo-Less Liposomal Formulation on Dietary Obesity-Related Metabolic Disorders in Mice

Area of Science:

• Immunology
• Metabolic disease
• Lipid-based therapeutics

Background:

• Obesity is linked to inflammation driven by tissue macrophage infiltration, creating a self-perpetuating cycle.
• Current obesity treatments often involve medication and strict dietary changes.

Purpose of the Study:

• To investigate the potential of cargo-less liposomes (UTS-001) as a novel therapeutic for obesity and related metabolic dysfunction.
• To evaluate UTS-001's ability to modulate macrophage activity and improve metabolic parameters in a mouse model.

Main Methods:

• Development of cargo-less liposomes (UTS-001) using 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC).
• Administration of UTS-001 to mice on a high-fat diet (HFD) to assess effects on weight gain, glucose metabolism, and inflammation.
• Analysis of macrophage populations in adipose tissue and liver, and key metabolic markers related to gluconeogenesis and thermogenesis.

Main Results:

• UTS-001 demonstrated immunomodulatory effects, reducing macrophage numbers in fat and liver tissues.
• The liposomes downregulated hepatic gluconeogenesis markers and upregulated thermogenesis markers.
• Significant improvements were observed in glucose tolerance, insulin sensitivity, and reduced fat accumulation in HFD-fed mice treated with UTS-001.

Conclusions:

• UTS-001 effectively targets tissue-resident macrophages, suppressing inflammation associated with high-fat diet-induced obesity.
• This therapeutic strategy shows promise for improving weight management and glycemic control.
• UTS-001 represents a potential novel agent for managing obesity and associated metabolic disorders.